The Microbiome Business & Science Briefing

Reporting on The Latest Microbiome Business & Scientific Developments

TRENDING

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Editor's Choice /Pharma & Human Health

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

BY Laurence Zitvogel · APR 15, 2022 · 1 MIN READ

Credit: INSERM

Laurence Zitvogel